Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06411990

Laser In Situ Fenestration Study

The goal of this clinical trial is to learn about a new device, named the LIFE device, to treat people with aneurysms (swellings) in the aorta (large, main blood vessel that delivers blood from the heart to the body). The main questions this trial aims to answer are:

* If the LIFE device works to treat aortic aneurysms * What medical problems participants have when the LIFE device is used Participants will undergo treatment with the LIFE device and thereafter at 30 days, 6 months, 1 year, 2 years, 3 years, 4 years, and 5 years have their pulses checked, bloodwork to check kidney function (BUN and serum creatinine), and a CT scan of the aneurysm area.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

In this clinical trial the LIFE device is used to treat people with aneurysms in the aorta near the kidney arteries (called juxtarenal or pararenal aortic aneurysms). Tubes, called stent grafts, are typically inserted through blood vessels in the groin and placed inside the aorta in the abdomen and chest area (endovascularly placed) to cover the tear or leak in the aorta. The LIFE device covers the tear or leak and has side branches to let blood flow into the kidney, spleen, intestine, or liver arteries. Participants in this study are not candidates for endovascular devices approved for endovascular aorta repair to the juxtarenal or pararenal aorta, not candidates for open repair, not willing to travel to sites that have access to manufacturer-made endovascular devices, and patients for whom there are no favorable alternatives, for example, urgent, symptomatic, and emergency cases.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aortic aneurysm >5.5 cm in a man or > 5.0 cm in a woman or rapid expansion deemed at significant risk for rupture in the juxtarenal or pararenal aorta.
  • Endovascular aortic repair requiring coverage of renovisceral branches.
  • Not candidate or at high risk for open repair. For example, but not exclusively, due to renal dysfunction, previous abdominal surgery, obese body habitus, previous coronary bypass grafts or high cardiac risk, chronic obstructive pulmonary disease (COPD) or on oxygen at rest, poorly controlled diabetes, current smoking, or antiplatelet or anticoagulation use.
  • Proximal aortic landing zone in Zone 5 of the aorta or previous graft of at least 10 mm in length and diameter of between 20 and 40 mm.
  • Distance ≥ 5 mm between top of graft fabric and renovisceral branch orifice.
  • At least a 5 mm iliofemoral artery to accept the endovascular stent graft device and an axillary brachial artery of sufficient diameter to accept the laser catheter.
  • Renovisceral diameter between 4 and 13 mm at the origin.
  • At the time of case planning, the patient's anatomy appears amenable to complete exclusion of the aneurysm with laser fenestration techniques.
  • Not willing or able to travel to sites that have access to manufacturer-made investigational endovascular devices.
  • Not a candidate for currently approved endovascular options.
  • 18 years or older.
  • Patient or legally authorized representative agrees to participate in the study and provides written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization.
  • Patient is able and willing to meet all study requirements, including participating in follow up evaluations and attending required assessment visits.

Exclusion criteria

  • Known sensitivities or allergies to the materials of construction of the devices, including Nitinol, polyester, Platinum-Iridium, stainless steel, fluoropolymer, and heparin.
  • Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed.
  • Uncorrectable coagulopathy.
  • Body habitus that would inhibit radiographic visualization of the aorta or exceeds the safe capacity of equipment.
  • Concurrent participation in another research protocol for investigation of an experimental therapy.
  • Subject has been judged to be unsuitable for participation in the study by the Investigator for any reason.

Treatment and study plan

Fenestrated Endovascular Aneurysm Repair using the LIFE Device System

Device

Fenestrated Endovascular Aneurysm Repair

Other names: Medtronic Valiant Thoracic Stent Graft with the Captive Delivery System, Medtronic Endurant II Stent Graft System, Medtronic Endurant IIs Stent Graft System and/or, Medtronic Endurant Aorto-uni-iliac (AUI) Stent Graft System, GORE VIABAHN VBX Balloon Expandable Endoprostheses, Spectranetics CVX-300 Excimer Laser System with the Spectranetics Turbo-Elite Laser Atherectomy Catheter

Primary outcomes

  1. Number of participants with freedom from death and major adverse events (MAE)

    Time frame: 30 days

    Number of subjects with freedom from all cause mortality and freedom from major adverse events. Major adverse events include myocardial infarction, chronic renal insufficiency / chronic renal failure requiring, dialysis, bowel ischemia, stroke, paraplegia or paraparesis, and prolonged ventilatory support.

  2. Number of participants with device procedure technical success and freedom from endoleak, migration, aortic enlargement, aortic rupture, and aortic or branch-related reinterventions in

    Time frame: 12 months

    Device technical success (at the end of index procedure) and freedom from Type I and III endoleak, device migration ≥ 10 mm, aortic enlargement ≥ 5 mm, aortic rupture, and aortic or branch-related reinterventions, including conversion to open repair (within 12 months of the index procedure)

Secondary outcomes

  1. Number of participants with delivery and deployment of the LIFE Device System

    Time frame: Procedure

    Ability to deliver and deploy the LIFE Device System

  2. Number of participants with delivery and deployment of the thoracic/abdominal stent graft

    Time frame: Procedure

    Ability to deliver and deploy the thoracic/abdominal stent graft

  3. Number of participants with coverage of intended aneurysm

    Time frame: Procedure

    Ability to cover the intended aneurysm

  4. Number of participants with contrast flow into target renovisceral vessels

    Time frame: Procedure

    Contrast flow into the target renovisceral vessels

  5. Estimated blood loss

    Time frame: Procedure

    Estimated blood loss

  6. Ventilator days

    Time frame: From Procedure until the date of Hospital Discharge, typically 1-2 days

    Ventilator days

  7. Days to oral intake

    Time frame: From Procedure until the date of Hospital Discharge, typically 1-2 days

    Days to oral intake

  8. Intensive Care Unit (ICU) days

    Time frame: From Procedure until the date of Hospital Discharge, typically 1-2 days

    ICU days recorded

  9. Days to hospital discharge

    Time frame: From Procedure until the date of Hospital Discharge, typically 1-2 days

    Days to hospital discharge

  10. Procedure time

    Time frame: Procedure

    Procedure time (minutes)

  11. Fluoroscopy time

    Time frame: Procedure

    Fluoroscopy time (minutes)

  12. Endoleak rate

    Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

    Endoleak rate at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

  13. Number of participants with device integrity failure

    Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

    Device integrity failure (e.g., fracture) at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

  14. Number of participants with branch vessel device events

    Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

    Branch vessel device events (i.e., kink, stenosis, or occlusion at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

  15. Number of participants with aortic growth

    Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

    Aortic growth - defined as an increase ≥ 5 mm in maximal aortic diameter in any segment at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

  16. Number of participants with unplanned secondary procedures

    Time frame: 5 Years

    Unplanned secondary procedures throughout follow-up (e.g., unanticipated aortic or branch-related reoperation)

  17. Number of participants with device migration

    Time frame: 6 Months, and 1, 2, 3, 4, and 5 Years

    Device migration (radiographic), antegrade or retrograde movement of more than 10 mm relative to anatomic landmarks identified on the first (30 Day) post-operative CT scan, at 6 Months, and 1, 2, 3, 4, and 5 Years

  18. All adverse events

    Time frame: 5 Years

    All adverse events throughout 5 year follow-up, including if MAE, serious adverse event (SAE) or unanticipated adverse device effect (UADE), and the relationship of the AE to the LIFE Procedure and LIFE Device System

  19. Freedom from aneurysm-related mortality

    Time frame: 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

    Freedom from aneurysm-related mortality at 30 Days, 6 Months, and 1, 2, 3, 4, and 5 Years

  20. Freedom from all-cause mortality

    Time frame: 6 Months and 1, 2, 3, 4, and 5 Years

    Freedom from all-cause mortality at 6 Months and 1, 2, 3, 4, and 5 Years

Study contacts

Contact information is provided by the study sponsor or research team.

Jennifer Randolph, Nurse, Clinical Research, RN, BSN

CONTACT

[email protected]

573-882-4387

Sponsors and collaborators

Lead sponsor

Jonathan Bath

Other

Collaborators

  • University of Missouri-Columbia

Registry information

Official study title

Laser In Situ Fenestration for Endovascular Aortic Repair (LIFE) Study

Acronym: LIFE

Important dates

Study start
2024
Primary completion
2027
Study completion
2031
First posted
May 14, 2024
Registry last updated
Mar 28, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.